Completed PHASE2 INTERVENTIONAL NCT00003887

Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation

Donor Lymphocyte Infusion (DLI) as Adoptive Immunotherapy for Relapse Malignancies After Allogeneic Hematopoietic Transplantation

Sponsor: Fred Hutchinson Cancer Center

Conditions Breast Cancer Chronic Myeloproliferative Disorders Gestational Trophoblastic Tumor Kidney Cancer Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Neuroblastoma Ovarian Cancer Sarcoma Testicular Germ Cell Tumor

Interventions peripheral blood lymphocyte therapy

Updated 6 times since 2017 Last updated: Nov 28, 2011 Started: Aug 31, 1998 Completion: Feb 28, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00003887, this PHASE2 trial focuses on Breast Cancer and Chronic Myeloproliferative Disorders and remains completed. Sponsored by Fred Hutchinson Cancer Center, it has been updated 6 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
May 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — May 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Data source: Fred Hutchinson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seattle, United States